Last reviewed · How we verify
Bifidobacterium animalis subsp. lactis
Bifidobacterium animalis subsp. lactis is a probiotic bacterium that modulates the gut microbiota and enhances intestinal barrier function and immune tolerance.
Bifidobacterium animalis subsp. lactis is a probiotic bacterium that modulates the gut microbiota and enhances intestinal barrier function and immune tolerance. Used for Inflammatory bowel disease (Crohn's disease or ulcerative colitis), Irritable bowel syndrome, Antibiotic-associated diarrhea.
At a glance
| Generic name | Bifidobacterium animalis subsp. lactis |
|---|---|
| Sponsor | University of Sao Paulo |
| Drug class | Live biotherapeutic product (probiotic) |
| Modality | Biologic |
| Therapeutic area | Gastroenterology / Immunology |
| Phase | Phase 3 |
Mechanism of action
This live biotherapeutic product colonizes the gastrointestinal tract and produces metabolites that strengthen tight junctions, reduce pathogenic bacterial overgrowth, and promote regulatory T cell differentiation. By restoring eubiotic balance and reducing intestinal inflammation, it may ameliorate conditions associated with dysbiosis and impaired mucosal immunity.
Approved indications
- Inflammatory bowel disease (Crohn's disease or ulcerative colitis)
- Irritable bowel syndrome
- Antibiotic-associated diarrhea
Common side effects
- Gastrointestinal disturbance (bloating, gas, abdominal discomfort)
- Diarrhea
- Constipation
Key clinical trials
- To Investigate the Effects of Bifidobacterium Animalis Subsp. Lactis XLTG11 on Growth and Development, Incidence of Allergy and Immune Function in Infants (PHASE2)
- Probiotic Intervention in Constipation (NA)
- Study to Evaluate the Efficacy of Lactobacillus Crispatus M247 in the Prevention and Treatment of Recurrent Urinary Tract Infections (NA)
- Biotics Intervention Oriented to Rescue From Environmental Pollution Inflammatory Responses (NA)
- Impact of a Probiotic Supplementation With Lifestyle Modification on Liver Steatosis, Fibrosis, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (NA)
- The Effect of Probiotics on Gut Microbiota Changes in Healthy Chinese Adults During Short-Term European Travel: A Randomised, Double-Blind, Placebo-Controlled Clinical Trial (PHASE2)
- Probiotics for Women (NA)
- Effect of Probiotics on Relapsing-Remitting Multiple Sclerosis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |